Every peptide, mapped to the body.

153 peptides, from approved drugs to compounds still in trials, sorted by where they act.

FDA-approved
In clinical trials
Wellness and performance
Cosmetic and topical

Loading the body

In clinical trials

Digestive & weight

Survodutide

Also called BI 456906

EvidenceDeep research

ClassGLP-1 / glucagon dual agonist

Survodutide is an investigational GLP-1 and glucagon dual agonist studied for obesity and liver disease. Learn how it works, what trials show, and its status.

Reviewed by: William Maish, MD MBA MPH, Clinical Product Lead
Published: October 5, 2026
Last updated: October 5, 2026

Key takeaway

Survodutide is an investigational GLP-1 and glucagon dual-receptor agonist, developed by Boehringer Ingelheim with Zealand Pharma, given as a once-weekly injection for obesity and liver disease (MASH). In a Phase 2 trial and a Phase 3 liver trial, it improved liver disease and reduced body weight, with a positive Phase 3 obesity topline also reported. As of 2026 it is not approved anywhere.

At a glance

FDA status	Investigational peptide, not approved by the FDA or any regulator
What it is	GLP-1 and glucagon receptor dual agonist given as a once-weekly injection
Research	Positive Phase 2 and Phase 3 results in liver disease and a positive Phase 3 obesity topline
How it works	Glucagon component intended to add direct liver-fat effects
Evidence strength	Deep research

What is survodutide?

Survodutide is an experimental dual-receptor agonist that activates the glucagon and GLP-1 receptors, discovered by Zealand Pharma and developed by Boehringer Ingelheim under the code BI 456906. It is given as a once-weekly injection and is in development for obesity and for metabolic dysfunction-associated steatohepatitis (MASH). It is investigational and not approved.

How does it work?

Survodutide combines two hormone actions. The glucagon receptor¹ arm is intended to increase energy expenditure and promote fat breakdown in the liver, while the GLP-1 receptor² arm reduces appetite and supports weight loss. The combination is designed to pair weight loss with direct liver-fat reduction, which is the rationale for its use in MASH. This describes the proposed mechanism rather than a proven outcome.

Is it FDA-approved?

No. Survodutide is investigational and not approved by the FDA or EMA. According to the developers, Phase 3 programs in obesity and in MASH are active, and a positive Phase 3 obesity topline has been reported via press release.

What does the research show?

The evidence spans Phase 2 and Phase 3:

Trial	Population	Result
Phase 2 trial¹, according to PubMed	Biopsy-confirmed MASH	Met its primary goal of histologic improvement without worsening fibrosis compared with placebo over 48 weeks
Phase 3 trial³ (SYNCHRONIZE-MASLD)	Adults with obesity and fatty liver	Far more participants on survodutide achieved a large reduction in liver fat than on placebo, with a mean weight change of about −12% versus −1%
Phase 3 obesity trial	Obesity	Topline mean weight loss of about 17%, reported via company press release⁴, with full peer-reviewed results pending

These are consistent, replicated results, though the drug is not approved.

More for digestive & weight

Sources: the Phase 2 MASH trial (Sanyal et al., New England Journal of Medicine, 2024, DOI: 10.1056/NEJMoa2401755¹) and the Phase 3 SYNCHRONIZE-MASLD trial (Kaplan et al., Nature Medicine, 2026, DOI: 10.1038/s41591-026-04479-3³), both indexed on PubMed; and Boehringer Ingelheim / Zealand Pharma obesity trial announcements. This document is educational, is not medical advice or a health claim, and is not an offer to sell any product.